Hereditary Transthyretin Amyloidosis
Early diagnosis key for management, QOL in transthyretin amyloidosis
Taimur Sher, MBBS, MD a hematologist, internist and oncologist at the Mayo Clinic Cancer Center who leads the Multispecialty Amyloidosis Clinic at Mayo Clinic in Jacksonville, Florida, spoke with Healio about how to recognize and diagnose transthyretin amyloidosis, the newest FDA-approved treatments and the importance of genetic counseling in disease management.
Making tafamidis cost-effective for TTR amyloid cardiomyopathy may require 93% price reduction
Although tafamidis can provide substantial clinical benefit for patients with transthyretin amyloid cardiomyopathy, the drug exceeds cost-effectiveness thresholds at its current list price of $225,000 per year, according to an analysis published in Circulation.
Genetic variant linked to HF in people of African American or Latino ancestry
The TTR V122I genetic variant was significantly linked to HF among patients of African or Latino ancestry, according to a study published in JAMA.